false
0001855644
0001855644
2025-10-08
2025-10-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Warrants [Member]
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
8-K
Current
Report
Pursuant
to Section 13 or
15(d)
of the Securities Exchange Act of 1934
October 8, 2025
Date of Report (Date of earliest event reported)
Zura Bio Limited
(Exact name of registrant as specified in its charter)
| Cayman Islands |
|
001-40598 |
|
98-1725736 |
(State or other jurisdiction of
incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
1489 W. Warm Springs Rd. #110
Henderson, NV 89014
(Address of principal
executive offices, including zip code)
(702) 825-9872
(Registrant’s telephone
number, including area code)
(Former name or former address,
if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name
of each exchange on which
registered |
| Class A Ordinary Shares, par value $0.0001 per share |
|
ZURA |
|
The Nasdaq Stock Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 8, 2025, Robert Lisicki, Chief
Executive Officer (principal executive officer) and member of the Board of Directors of Zura Bio Limited (the “Company”)
informed the Company that he is taking a medical leave of absence, effective October 10, 2025. Accordingly, effective October
10, 2025, the Company’s Board of Directors appointed Kim Davis, Chief Operating Officer, Chief Legal Officer and Corporate
Secretary, to serve as the Company’s interim Chief Executive Officer and interim principal executive officer, in
addition to her current duties.
Biographical and other information for Ms. Davis
is set forth in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April
23, 2025 and is incorporated herein by reference. Ms. Davis is not party to any arrangement or understanding pursuant to which she was
appointed as an officer, nor is she party to any transactions required to be disclosed pursuant to Item 404(a) of Regulation
S-K. There are no family relationships between Ms. Davis and any of the Company’s directors or executive officers.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
ZURA BIO LIMITED |
| |
|
| Date: October 10, 2025 |
By: |
/s/ Kim Davis |
| |
|
Kim Davis |
| |
|
Interim Chief Executive Officer, Chief Operating Officer, Chief Legal Officer and Corporate Secretary |
